Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Fernanda Costas C. de Faria"'
Autor:
Danielle Almeida Braggio, Fernanda Costas C. de Faria, David Koller, Feng Jin, Abeba Zewdu, Gonzalo Lopez, Kara Batte, Lucia Casadei, Meng Welliver, Stephen K. Horrigan, Ruolan Han, Jeffrey L. Larson, Anne M. Strohecker, Raphael E. Pollock
Publikováno v:
PLoS ONE, Vol 17, Iss 10 (2022)
Mutation in the CTNNB1 gene, leading to a deregulation of the WTN/β-catenin pathway, is a common feature of desmoid tumors (DTs). Many β-catenin inhibitors have recently been tested in clinical studies; however, BC2059 (also referred as Tegavivint)
Externí odkaz:
https://doaj.org/article/e2356868798d476dbb57de27687e8a34
Autor:
Sayumi Tahara, Fernanda Costas C. de Faria, Patricia Sarchet, Federica Calore, Joe Sharick, Jennifer L. Leight, Lucia Casadei, Raphael E. Pollock
Publikováno v:
Human Cell. 36:1081-1089
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::354668d2ef5eda78786081db5ca3dd31
https://doi.org/10.1007/s13577-023-00865-y
https://doi.org/10.1007/s13577-023-00865-y
Autor:
Lucia Casadei, Patricia Sarchet, Fernanda Costas C. de Faria, Federica Calore, Giovanni Nigita, Sayumi Tahara, Luciano Cascione, Martin Wabitsch, Francis J. Hornicek, Valerie Grignol, Carlo M. Croce, Raphael E. Pollock
Publikováno v:
Journal of Extracellular Vesicles. 11
EVs have emerged as an important component in tumour initiation, progression and metastasis. Although notable progresses have been made, the detection of EV cargoes remain significantly challenging for researchers to practically use; faster and more
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e30fe57170858a2f07a4c7184e632d1
https://doi.org/10.1002/jev2.12251
https://doi.org/10.1002/jev2.12251
Autor:
Fernanda Costas C, de Faria, Maria Eduarda Bento, Leal, Paula Sabbo, Bernardo, Paulo R R, Costa, Raquel C, Maia
Publikováno v:
Anti-cancer agents in medicinal chemistry. 15(3)
Chronic myeloid leukemia (CML), a myeloproliferative disorder characterized by the BCR-ABL oncoprotein, presents its treatment based on tyrosine kinase inhibitors (TKIs), mainly imatinib. However, despite its clinical success, almost 30% of all CML p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::665fbcce2b177b12302a4452798b307c
https://pubmed.ncbi.nlm.nih.gov/25964959
https://pubmed.ncbi.nlm.nih.gov/25964959